Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study to Characterize the Patient Population Diagnosed with Sarcopenia

Next Previous
Trial Profile

An Observational Study to Characterize the Patient Population Diagnosed with Sarcopenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarconeos (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions
  • Acronyms SARA-OBS
  • Sponsors Biophytis

    • Most Recent Events

    • 14 Dec 2020 According to a Biophytis media release, data from this study was presented at the 13th international conference on sarcopenia, cachexia andwasting disorders (SCWD) on Saturday December 12th, 2020.
    • 14 Dec 2020 Results published in the Biophytis media release
    • 03 Mar 2020 According to a Biophytis media release, the company will make a presentation at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020,11th March 2020 in Toulouse, France) which will include preliminary results of SARA-OBS study and insights on the SARA-INT recruitment strategies, including inclusion criteria, as well as the baseline characteristics of the first patients.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top